clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Myxoma D009232 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Adamek RJ et al. Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection. 1995 Am. J. Gastroenterol. pmid:7801936
Gisbert JP et al. Esomeprazole-based therapy in Helicobacter pylori eradication: any effect by increasing the dose of esomeprazole or prolonging the treatment? 2005 Am. J. Gastroenterol. pmid:16128936
Isomoto H et al. Impact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. 2005 Am. J. Gastroenterol. pmid:16086706
Pamuk ON et al. Are Turkish Helicobacter pylori strains gaining resistance against clarithromycin? 2000 Am. J. Gastroenterol. pmid:10926000
Sontag SJ et al. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin. 2001 Am. J. Gastroenterol. pmid:11374672
Laine L et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. 2003 Am. J. Gastroenterol. pmid:12650788
Schaeverbeke T et al. Should we eradicate Helicobacter pylori before prescribing an NSAID? Result of a placebo-controlled study. 2005 Am. J. Gastroenterol. pmid:16393213
Kume K et al. Disappearance of both MALT lymphoma and hyperplastic polyps in the stomach after eradication of Helicobacter pylori. 2001 Am. J. Gastroenterol. pmid:11569719
al-Assi MT et al. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. 1994 Am. J. Gastroenterol. pmid:8053435
Take S et al. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. 2003 Am. J. Gastroenterol. pmid:14638340
de Bortoli N et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. 2007 Am. J. Gastroenterol. pmid:17313499
Mohar A et al. Eradication rate of Helicobacter pylori in a Mexican population at high risk for gastric cancer and use of serology to assess cure. 2002 Am. J. Gastroenterol. pmid:12385434
De Francesco V et al. Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia? 2002 Am. J. Gastroenterol. pmid:12385470
Chey WD and Wong BC American College of Gastroenterology guideline on the management of Helicobacter pylori infection. 2007 Am. J. Gastroenterol. pmid:17608775
Savarino V et al. What is the meaning of ranitidine in successful triple-therapy against Helicobacter pylori infection? 1995 Am. J. Gastroenterol. pmid:8540537
Gisbert JP et al. Response to article by Forné et al. 1996 Am. J. Gastroenterol. pmid:8561132
Uygun A et al. Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. 1999 Am. J. Gastroenterol. pmid:10520880
Cremonini F et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. 2002 Am. J. Gastroenterol. pmid:12425542
Peterson WL et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. 1993 Am. J. Gastroenterol. pmid:8237933
Nista EC et al. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication. 2006 Am. J. Gastroenterol. pmid:16968503
van Zanten SV and Thompson K Should the presence of polymorphisms of CYP2C19 enzymes influence the choice of the proton pump inhibitor for treatment of Helicobacter pylori infection? 2006 Am. J. Gastroenterol. pmid:16863548
Froehlich F et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. 2001 Am. J. Gastroenterol. pmid:11513170
Rokkas T et al. Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. 2006 Am. J. Gastroenterol. pmid:16928256
Sánchez-Delgado J et al. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. 2008 Am. J. Gastroenterol. pmid:18564109
Sugimoto M et al. Prevention of hemorrhage from intradiverticular ulcer in the duodenum by Helicobacter pylori eradication. 2000 Am. J. Gastroenterol. pmid:10685780
Coelho LG et al. Once-daily Helicobacter pylori treatment to family members of gastric cancer patients. 2000 Am. J. Gastroenterol. pmid:10710099
Pilotto A et al. In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin. 2000 Am. J. Gastroenterol. pmid:10710100
Hansen JM et al. Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study. 2008 Am. J. Gastroenterol. pmid:18445098
Vakil N H. pylori treatment: new wine in old bottles? 2009 Am. J. Gastroenterol. pmid:19098845
Watson JB and Moss SF Will H. pylori stagger under the weight of this LOAD? A novel but expensive eradication regimen. 2011 Am. J. Gastroenterol. pmid:22056576
Rokkas T et al. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. 2009 Am. J. Gastroenterol. pmid:19098844
Lazzaroni M et al. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. 1997 Am. J. Gastroenterol. pmid:9128316
Sapone A et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. 2003 Am. J. Gastroenterol. pmid:12809821
van der Hulst RW et al. Therapeutic options after failed Helicobacter pylori eradication therapy. 1996 Am. J. Gastroenterol. pmid:8931413
Alder JD et al. Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies. 1996 Am. J. Gastroenterol. pmid:8931416
Zhou L et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. 2014 Am. J. Gastroenterol. pmid:24642580
Sharma VK et al. A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. 1999 Am. J. Gastroenterol. pmid:10566709
Levy M et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. 2002 Am. J. Gastroenterol. pmid:11866264
Christopher K et al. Clarithromycin use preceding fulminant hepatic failure. 2002 Am. J. Gastroenterol. pmid:11866297
Narayani RI et al. Resolution of collagenous colitis after treatment for Helicobacter pylori. 2002 Am. J. Gastroenterol. pmid:11866305
Stack WA et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. 1998 Am. J. Gastroenterol. pmid:9772054
Suzuki S et al. The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. 2016 Am. J. Gastroenterol. pmid:27185079
Adamek RJ and Bethke TD Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group. 1998 Am. J. Gastroenterol. pmid:9772056
Ali' A et al. A second-line anti-Helicobacter pylori therapy in patients with previously failed treatment. 1999 Am. J. Gastroenterol. pmid:10445583
Fennerty MB Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. 1998 Am. J. Gastroenterol. pmid:9448162
Lamouliatte H et al. Dual therapy using a double dose of lansoprazole with amoxicillin versus triple therapy using a double dose of lansoprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori infection: results of a prospective randomized open study. 1998 Am. J. Gastroenterol. pmid:9732938
Forné M et al. Randomized clinical trial comparing two one-week triple-therapy regimens for the eradication of Helicobacter pylori infection and duodenal ulcer healing. 1998 Am. J. Gastroenterol. pmid:9448170
Hsu PI et al. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. 2005 Am. J. Gastroenterol. pmid:16279889
Sullivan B et al. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. 2002 Am. J. Gastroenterol. pmid:12385435
Chiba N Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. 1996 Am. J. Gastroenterol. pmid:8855737
Labenz J and Börsch G Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. 1995 Am. J. Gastroenterol. pmid:7733070
Gisbert JP et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. 2008 Am. J. Gastroenterol. pmid:17764498
Forné M et al. Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. 1995 Am. J. Gastroenterol. pmid:7733075
Dohil R et al. Effective 2-wk therapy for Helicobacter pylori disease in children. 1997 Am. J. Gastroenterol. pmid:9040199
Lerang F et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? 1997 Am. J. Gastroenterol. pmid:9040200
Odaka T et al. Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy. 2002 Am. J. Gastroenterol. pmid:11922552
Giannini E et al. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens. 2000 Am. J. Gastroenterol. pmid:11051345
Vakil N and Cutler A Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. 1999 Am. J. Gastroenterol. pmid:10235192
Scholte GH et al. Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation to histological parameters and effects on therapy. 2002 Am. J. Gastroenterol. pmid:12135019
Gatta L et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. 2009 Am. J. Gastroenterol. pmid:19844205
Kim CG et al. Preoperative versus postoperative Helicobacter pylori eradication therapy in gastric cancer patients: a randomized trial. 2008 Am. J. Gastroenterol. pmid:17714557
Trevisani L et al. A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. 1998 Am. J. Gastroenterol. pmid:9517646
Zullo A et al. Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. 1997 Am. J. Gastroenterol. pmid:9362185
Kawasaki M et al. Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. 1997 Am. J. Gastroenterol. pmid:9382064
Adamek RJ et al. Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection. 1997 Am. J. Gastroenterol. pmid:9382084
Sirimontaporn N et al. Ten-day sequential therapy of Helicobacter pylori infection in Thailand. 2010 Am. J. Gastroenterol. pmid:20010919
Basu PP et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. 2011 Am. J. Gastroenterol. pmid:21989146
Murata H et al. Evaluation of the PyloriTek test for detection of Helicobacter pylori infection in cases with and without eradication therapy. 1998 Am. J. Gastroenterol. pmid:9820380
Laine L et al. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. 1998 Am. J. Gastroenterol. pmid:9820381
Moayyedi P and Malfertheiner P Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? 2009 Am. J. Gastroenterol. pmid:19956122
Zullo A et al. A quintuple therapy for H. pylori eradication. 2007 Am. J. Gastroenterol. pmid:17958765
Hasegawa T et al. Image of the month: Disseminated Nontuberculous Mycobacteriosis. 2015 Am. J. Gastroenterol. pmid:26673493
Schwartz H et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. 1998 Am. J. Gastroenterol. pmid:9576452
de Boer WA et al. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. 1998 Am. J. Gastroenterol. pmid:9672338
Calvet X et al. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. 2005 Am. J. Gastroenterol. pmid:16086704
Park CS et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. 2014 Am. J. Gastroenterol. pmid:25091062
Vakil N and Fennerty MB Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. 1996 Am. J. Gastroenterol. pmid:8607487
Treiber G The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. 1996 Am. J. Gastroenterol. pmid:8607488
Shaheen N and Grimm IS Fulminant hepatic failure associated with clarithromycin. 1996 Am. J. Gastroenterol. pmid:8607519
Bardhan KD et al. Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. 1998 Am. J. Gastroenterol. pmid:9517644
Adamek RJ et al. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. 1998 Am. J. Gastroenterol. pmid:9517645
Vakil N Helicobacter pylori treatment: a practical approach. 2006 Am. J. Gastroenterol. pmid:16542285
Tursi A et al. Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication. 1996 Am. J. Gastroenterol. pmid:8759696
Jarbol DE et al. Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial. 2006 Am. J. Gastroenterol. pmid:16771937
Bytzer P Management of the dyspeptic patient: anything goes? 2006 Am. J. Gastroenterol. pmid:16771938
Manes G et al. Eradication of Helicobacter pylori and dosages of esomeprazole. 2006 Am. J. Gastroenterol. pmid:16771971
Sonnenberg A et al. The effect of antibiotic therapy on bleeding from duodenal ulcer. 1999 Am. J. Gastroenterol. pmid:10201462
Smoot DT et al. Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. 1999 Am. J. Gastroenterol. pmid:10201463
Fuccio L et al. Can sequential therapy for Helicobacter pylori eradication overcome clarithromycin resistance?: Data still do not support conclusions. 2010 Am. J. Gastroenterol. pmid:20606668
van der Wouden EJ et al. One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. 1998 Am. J. Gastroenterol. pmid:9707042
Laine L et al. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. 1999 Am. J. Gastroenterol. pmid:10201465
Nakao K et al. Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. 1997 Am. J. Gastroenterol. pmid:9177520
Maconi G et al. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? 2001 Am. J. Gastroenterol. pmid:11232676
Parasakthi N and Goh KL Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia. 1995 Am. J. Gastroenterol. pmid:7872306
Kadayifçi A et al. Low dose clarithromycin plus omeprazole eradicates Helicobacter pylori in duodenal ulcer disease. 1995 Am. J. Gastroenterol. pmid:7872307
Laine L et al. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. 1997 Am. J. Gastroenterol. pmid:9399755
Srinivasan R and Minocha A Cure of Helicobacter pylori: a hidden curse? 1997 Am. J. Gastroenterol. pmid:9399784
Nam SY et al. Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. 2010 Am. J. Gastroenterol. pmid:20571493
Veldhuyzen van Zanten S et al. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. 2003 Am. J. Gastroenterol. pmid:14499772
Luther J et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. 2010 Am. J. Gastroenterol. pmid:19755966